BioXyTran, Inc. — Tissue Regeneration for Life
BioXyTran, Inc. — Tissue Regeneration for Life Bioxytran Inc. (OTC: BIXT) is a late stage biotechnology company that is developing a first-in-class oxygen treatment platform for victims of brain stroke trauma. The company’s lead drug candidate, BXT-25, is getting ready to proceed to testing. BXT-25 has many properties of an existing, well tested drug, called […]
Orange Grove Bio: Filling the Gap in Preclinical Drug Development
Orange Grove Bio: Filling the Gap in Preclinical Drug Development Future Orange Grove Bio is a preclinical drug development company focused on driving down the cost of drug development and taking advantage of the exceptional science developed at universities across the country. Preclinical biopharma today represents one of the best opportunities in life sciences today. […]
An Interview with Kristin Bedard PhD, Chief Scientific Officer Kineta Immuno-Oncology Part 2
An Interview with Kristin Bedard PhD, Chief Scientific Officer Kineta Immuno-Oncology. KINETA, INC. – Innovation in Cancer Care, New Drugs in High Need Areas (PART 2). Part 2 In two previous articles, our readers were introduced to the Kineta, Inc. CEO Shawn Iadonato and Kristin Bedard PhD, the Chief Scientific Officer at the company. In […]
Selecting Therapies for Cancer Patients: Past, Present, and Future
Selecting Therapies for Cancer Patients: Past, Present, and Future Clifford Reid, PhD We are in the middle of a revolution in DNA sequencing, which has ushered in the era of precision medicine in cancer. Unfortunately, the impact of precision medicine has been quite limited, reaching only about 15% of cancer patients, and benefitting only about […]
An Interview with Kristin Bedard PhD, Chief Scientific Officer Kineta Immuno-Oncology
An Interview with Kristin Bedard PhD, Chief Scientific Officer Kineta Immuno-Oncology. KINETA, INC. – Innovation in Cancer Care, Developing (and Investing in) New Drugs in High Need Areas. Part 1 In a previous article, our readers were introduced to your co-founder and Kineta, Inc. CEO Shawn Iadonato. In that article we shared with our readers […]
Client Spotlight – ChemioCare
Client Spotlight – ChemioCare ChemioCare is a biotechnology company focused on improving the profile of approved drugs with a proprietary delivery system. It develops unique transdermal patches, delivering drugs through the skin to improve efficacy and/or reduce toxicities when compared to the original oral or IV forms. Compared to drug development of a new molecular […]
New Therapeutic Options for Cancer Patients
New Therapeutic Options for Cancer Patients By Clifford Reid, PhD Some recent scientific publications further support the value of Travera’s approach to determining which cancer drugs to give to which cancer patients by direct testing: that is, removing cancer cells from each patient and directly measuring the response those cancer cells to many different cancer […]
Kineta – Developing Novel Immunotherapies That Transform Patients’ Lives
Kineta – Developing Novel Immunotherapies That Transform Patients’ Lives Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs. The company’s management team leverages expertise in immunology, drug development and corporate finance to advance a focused pipeline of investigational drugs in oncology, neuroscience and virology. […]
If anyone you know has been affected by Parkinson’s, Alzheimer’s or ADHD, LikeMinds is a company you should know more about
LikeMinds is developing a brain imaging agent that is intended to support the early diagnosis of dopamine mediated neurological diseases such as Parkinson’s, Alzheimer’s, ADHD, depression, addiction and schizophrenia. The facts are clear: 68.5 million Americans require accurate, precise diagnosis of degenerative brain diseases yet current imaging tools lack the required precision and economic value […]